HUMAN PAPILLOMAVIRUS SEROTYPE 58 WHOLE
Human Papillomavirus Infection
Beijing Health Guard Biotechnology, IncvaccinePhase 3Active
BB
70/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 58/ 100
- Competitive Position
- 95/ 100
Competitive context
9 Active assets in the Human Papillomavirus Infection cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Gardasil 9 Vaccine Eunice Dube | Phase 4 | BBB |
Recombinant Nonavalent Human Papillomavirus Vaccine Beijing Health Guard Biotechnology, Inc | Phase 3 | BB |
Hepatitis B Virus Vaccine Eunice Dube | Phase 4 | BB |
FLUOROURACILUM AIDS Malignancy Consortium | Phase 3 | BB |
Imiquimod AIDS Malignancy Consortium | Phase 3 | B |
View all 16 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →